RxDoctor Payments Data

Behrooz Yagoobian, MD

Family Medicine · Paramount, CANPI 1780613570

Payments from drug & device makers

$805in general payments, 2019–2025

Across 31 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$256
  • Insightec,inc$147
  • Merck$115
  • Amarin Pharma, Inc.$86
  • Sanofi Pasteur Inc.$68
  • Bayer$61
  • plus $72 from 2 others

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$805 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$36,169
Medicare patients
50
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate108$67,458
JardianceEmpagliflozin37$23,867
EliquisApixaban31$23,688
Incruse ElliptaUmeclidinium Bromide34$11,673
FarxigaDapagliflozin Propanediol20$11,299
XareltoRivaroxaban14$9,232
ArexvyRsvpref3 Antigen/As01e/Pf28$8,192
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,649
MyrbetriqMirabegron13$5,830
GemtesaVibegron11$5,079
Breo ElliptaFluticasone/Vilanterol12$4,723
Omega-3 Acid Ethyl Esters447$4,253
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$3,384
Arnuity ElliptaFluticasone Furoate12$3,267
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$115$67,458108 claims
GSKIncruse Ellipta, Arexvy, Breo Ellipta, Arnuity Ellipta, Shingrix$256$31,094103 claims
PfizerEliquis$18$23,68831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Paramount

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →